ErbB2 can be activated by its own overexpression or be transactivated by the heregulin polypeptide growth factor. Activation of ErbB2 leads to breast cancer cell proliferation, presumably by inducing the activation of extracellular signal-regulated kinases 1,2 (Erk1,2) and Akt. We have previously reported that the growth factor receptor bound protein-2 (Grb2) is required for the proliferation of ErbB2-overexpressing breast cancer cells. We investigated here whether Grb2 protein plays a role in heregulin-stimulated proliferation. Grb2 protein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2 inactivation. These ®ndings are similar to our earlier observations in ErbB2-overexpressing cells. Since Akt can also be activated by heregulin, the eects of Grb2 inhibition on Akt were examined. Akt was inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells. We then examined the eects of Grb2 downregulation on Akt in ErbB2-overexpressing cells in the absence of heregulin. Similar to heregulin-stimulated cells, Grb2 inhibition also led to Akt inactivation in ErbB2-overexpressing breast cancer cells. Our results indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stimulate the Akt pathway to propagate mitogenic signals. Oncogene (2000) 19, 6271 ± 6276.
Introduction
Ampli®cation of the ErbB2 (also known as Her2/neu) receptor tyrosine kinase gene is found in 20 ± 30% of breast cancer patients and is associated with poor patient prognosis (Slamon et al., 1987 (Slamon et al., , 1989 McCann et al., 1991; Paterson et al., 1991) . Unlike its other family members (EGFR, ErbB3 and ErbB4) , no ligand has yet been identi®ed for ErbB2. However, ErbB2 can be activated by its own overexpression (Pierce et al., 1991) , or be transactivated by heregulin (Holmes et al., 1992; Lupu et al., 1992; Peles et al., 1992) . Heregulin is a family of proteins identi®ed as ligands for the ErbB3 and ErbB4 receptor tyrosine kinases. Heregulin induces the formation of heterodimers between ErbB3 and ErbB2 or between ErbB4 and ErbB2, thereby transactivating ErbB2 (Plowman et al., 1993a,b; Sliwkowski et al., 1994; Carraway et al., 1995) . In fact, the eects of heregulin are predominantly mediated by ErbB2 since inhibiting the function of ErbB2 can block the cellular transformation and proliferation processes induced by heregulin (Alimandi et al., 1995; Lewis et al., 1996) . Heregulin stimulates these cellular processes, probably by activating multiple pathways, including those involving extracellular signal-regulated kinases 1,2 (Erk1,2) and phosphoinositol-3 (PI3) kinase (Fiddes et al., 1995; Marte et al., 1995; Sepp-Lorenzino et al., 1996) .
Upon activation by heregulin or its overexpression, ErbB2 becomes phosphorylated (Hazan et al., 1990) , and bound to the Src homology 2 (SH2) domain of the growth factor receptor bound protein-2 (Grb2) (Lowenstein et al., 1992) . Grb2 then uses its Src homology 3 (SH3) domains to bind to the guanine nucleotide exchange factor, Son of Sevenless (Sos) (Bon®ni et al., 1992; Chardin et al., 1993; Li et al., 1993; Simon et al., 1993) . Sos stimulates Ras by increasing the amount of guanine nucleotide triphosphate (GTP) on Ras (Downward et al., 1990 ). GTP-bound Ras then interacts with Raf (Dickson et al., 1992; Vojtek et al., 1993) , leading to the stimulation of MEK and Erk1,2 (de Vries-Smits et al., 1992; Howe et al., 1992) . Besides binding to Raf, GTP-bound Ras may bind to PI3 kinase (RodriguezViciana et al., 1994) , leading to the stimulation of Akt (Burgering and Coer, 1995; Franke et al., 1995) . Thus, Grb2 can potentially link activated ErbB2 to the activation of Erk1,2 and Akt in a Ras-dependent manner. Stimulation of the kinase activities of Erk1,2 and Akt have been shown to be important for mitogenesis (Marais and Marshall, 1996; Treisman, 1996; Alessi and Cohen, 1998) . Grb2 may therefore play a vital role in transducing the mitogenic signals of heregulin-activated ErbB2 to Erk1,2 and Akt.
We have previously used liposome-incorporated nuclease-resistant antisense oligodeoxynucelotides speci®c for the GRB2 mRNA (Tari et al., 1997 (Tari et al., , 1999 to inhibit Grb2 protein expression. We found that Grb2 downregulation led to growth inhibition of breast cancer cells that have overexpression of ErbB2 (Tari et al., 1999) , thus indicating that Grb2 is important for the proliferation of this type of breast cancer cells. Since the eects of heregulin are predominantly mediated by ErbB2 (Alimandi et al., 1995; Lewis et al., 1996) , we propose that Grb2 will also be important for the proliferation of heregulin-stimulated breast cancer cells. Here, we provide further evidence that Akt is involved in the mitogenic signaling mediated by Grb2.
Results

Liposomal Grb2 antisense oligodeoxynucleotides inhibited the growth of breast cancer cells stimulated by heregulin
Before examining the eects of Grb2 downregulation upon heregulin treatment, the growth-stimulatory eects of heregulin were investigated in two dierent breast cancer cell lines, T-47D and BT-474. These cells do not express endogenous heregulin but express ErbB3 and/or ErbB4 receptors and thus are able to bind to heregulin (Lewis et al., 1996) . These cells also dier in their ErbB2 expression levels (BT-47444T-47D) (Lewis et al., 1996) . Increasing doses of heregulin stimulated the proliferation of both cell lines even in cell culture medium supplemented with fetal bovine serum (FBS) (Figure 1) . At 80 and 100 ng/ml of heregulin, the proliferation of T-47D cells and BT-474 cells were stimulated up to 180 and 160% of untreated cells in mediums supplemented with 5 and 10% FBS, respectively.
We then investigated the eects of liposomal Grb2 antisense oligodeoxynucleotides (L-Grb2) on the growth of T-47D and BT-474 cells in the absence and presence of heregulin. Previously we had reported that Grb2 inhibition induced growth inhibition in breast cancer cells that have high, but not low, expression of ErbB2 (Tari et al., 1999) . Therefore, the low ErbB2-expressing T-47D cells were not expected to be growth inhibited by L-Grb2, but the high ErbB2-expressing BT-474 cells were expected to be inhibited by L-Grb2. Indeed, in the absence of heregulin, the growth of T-47D cells was not decreased by L-Grb2 (Figure 2a ), but the growth of BT-474 cells was selectively decreased by L-Grb2. BT-474 cell growth was decreased by 50% at 12 mM of L-Grb2 (Figure 2b ). Under identical conditions, liposomal control oligodeoxynucleotides (L-control) did not decrease the growth of T-47D and BT-474 cells (Figure 2a and b) .
In the presence of heregulin, L-Grb2 selectively decreased the proliferation of T-47D cells. When 12 mM of L-Grb2 was used, the growth of T-47D cells decreased by 75% while the same concentration of Lcontrol decreased growth only by 20% (Figure 2a) . A dose-dependent decrease in the proliferation of BT-474 cells was also observed when cells were coincubated with L-Grb2 and heregulin (Figure 2b ). At 12 mM of LGrb2, growth inhibition of BT-474 cells was similar in the absence or presence of heregulin (50% versus 58%). Our data indicate that L-Grb2 can inhibit the heregulin-stimulated proliferation of breast cancer cells regardless of the expression levels of ErbB2.
To further investigate the involvement of Grb2 protein in the heregulin-stimulated proliferation of breast cancer cells, MCF-7 cells transfected with heregulin (MCF-7/ T7) were used. MCF-7/T7 cells produce high levels of heregulin and thus have constitutively activated ErbB2 receptors in spite of their low ErbB receptors expression (Tang et al., 1996) . A dose-dependent decrease in cell proliferation was observed when MCF-7/T7 cells were incubated with various concentrations of L-Grb2, but not with L-control (Figure 3a) . At 12 mM of L-Grb2, the growth of MCF-7/T7 cells was decreased by 40%, while the same concentration of L-control only decreased growth by 4%. MCF-7 cells transfected with the control neomycin vector MCF-7/V were used as a negative control cell line. These cells have low levels of ErbB2 but do not express any heregulin; therefore ErbB2 is not activated in these cells (Tang et al., 1996) . As expected, growth inhibitory eects were not observed in MCF-7/V cells incubated with either L-Grb2 or L-control ( Figure  3b ). These data demonstrate that L-Grb2 can selectively inhibit the proliferation of MCF-7 cells which have activated ErbB2 due to the transfected heregulin gene.
Downregulation of Grb2 protein expression predominantly inhibited Akt activation in heregulin-transfected breast cancer cells
Western blot analysis was carried out to con®rm that L-Grb2 could selectively downregulate the expression of Grb2 protein as we had previously reported (Tari et al., 1997 (Tari et al., , 1999 . Compared with untreated cells, MCF-7/T7 cells treated with 10 mM of L-Grb2 for 3 days had a 39% decrease in Grb2 protein expression, while cells treated with the same concentrations of L-control had a 9% decrease in Grb2 protein expression (Figure 4 ). These data indicate that growth inhibition by L-Grb2 ( Figure 3 ) was mediated by speci®c downregulation of Grb2 protein expression.
We were interested in whether disruption of heregulin-induced growth signaling by Grb2 protein downregulation was due to inactivation of Erk1,2 and Akt, two of the downstream kinases associated with heregulin signaling (Fiddes et al., 1995; Marte et al., 1995; Sepp-Lorenzino et al., 1996; Liu et al., 1999) . So, we determined the phosphorylation, i.e. activation, levels of Erk1,2 and Akt in the same protein lysates in which Grb2 protein expression was downregulated. The protein levels of Erk1,2 and Akt did not change in MCF-7/T7 cells upon incubation with L-Grb2 or Lcontrol. The phosphorylation levels of Erk1,2 were also not signi®cantly changed after L-Grb2 treatment (Figure 4) . Compared with untreated cells, 10 mM of L-Grb2 decreased Erk1,2 activities by 15%, while 10 mM of L-control decreased Erk1,2 activities by 1%. On the other hand, L-Grb2 decreased the phosphorylation levels of Akt (Figure 4) . Akt activity was decreased by 62% in cells treated with 10 mM of L-Grb2 but only Densitometric scans were performed on Western blots to measure the ratios of Grb2 to Actin, phosphorylated Erk1,2 to Erk1,2, and phosphorylated Akt to Akt. b Grb2 inhibition was obtained by (1-ratio of Grb2 : Actin in treated cells/ratio of Grb2 : Actin in untreated cells)6100%.
c Erk1,2 inactivation was obtained by (1-ratio of phosphorylated Erk1,2 : Erk1,2 in treated cells/ratio of phosphorylated Erk1,2 : Erk1,2 in untreated cells)6100%. 12% by L-control. Our data indicate that Grb2 protein downregulation predominantly induces Akt inactivation in heregulin-transfected breast cancer cells.
Grb2 protein downregulation also led to Akt inactivation in ErbB2-overexpressing breast cancer cells
We have demonstrated that Grb2 downregulation could induce growth inhibition but not Erk1,2 inactivation in ErbB2-overexpressing breast cancer cells (Tari et al., 1999) . These ®ndings are similar to what we had described above for the heregulin-stimulated cells. Therefore, we speculate that Grb2 downregulation may also lead to Akt inactivation in ErbB2-overexpressing breast cancer cells. We examined the eects of Grb2 downregulation on Akt activities in MDA-MB-453 and BT-474 breast cancer cells, which express high levels of ErbB2 but do not express any heregulin. Similar to what was observed in breast cancer cells stimulated with heregulin, Grb2 inhibition also induced Akt inactivation in ErbB2-overexpressing breast cancer cells ( Figure 5 ). When MDA-MB-453 cells ( Figure 5a ) and BT-474 cells ( Figure 5b ) were incubated with 8 ± 12 mM of L-Grb2, Akt activity was inhibited by 34 ± 47%. But Akt activity was inhibited by 54% when same concentration of L-control were used. In all cases, L-Grb2 induced a decrease in Akt activity without decreasing Akt protein expression.
Discussion
Our results indicate that downregulation of Grb2 protein expression induced growth inhibition and Akt inactivation in ErbB2-overexpressing breast cancer cells as well as in heregulin-stimulated breast cancer cells. It is not surprising that Grb2 downregulation would lead to growth inhibition of heregulin-stimulated cells since there is considerable overlap in signaling between heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Both cell types require the presence and the activation of ErbB2 to induce cellular transformation and mitogenesis (Alimandi et al., 1995; Lewis et al., 1996) . The signaling induced by heregulin is initiated mainly from ErbB2 heterodimers while the signaling of ErbB2 overexpression is mainly from ErbB2 homodimers (Muthuswamy et al., 1999) .
We postulate that Grb2 regulates Akt activity in a Ras-dependent manner. Grb2 can bind directly to ErbB2 upon ErbB2 activation (Meyer et al., 1994) . Alternatively, Grb2 can bind indirectly to ErbB2 via Shc (Meyer et al., 1994; Ravichandran et al., 1995) . This is because activation of ErbB2 leads to increased tyrosine phosphorylation on Shc (Segatto et al., 1993) , which can bind to Grb2 and ErbB2 simultaneously (Meyer et al., 1994; Segatto et al., 1993) . So either directly or indirectly, Grb2 can link activated ErbB2 to Sos, thereby increasing Ras activity (Bon®ni et al., 1992; Chardin et al., 1993; Li et al., 1993; Simon et al., 1993) . Activated Ras may bind and activate PI3 kinase (Rodriguez-Viciana et al., 1994 , which can in turn stimulate Akt activity (Burgering and Coer, 1995; Franke et al., 1995) . Inhibition of Grb2 expression may therefore disrupt Ras/PI3 kinase/Akt signaling, and induce Akt inactivation. Stimulation of Ras/PI3 kinase activities, for example by expressing constitutively activated forms of Ras/PI3 kianse, should then block the inactivation of Akt by Grb2 downregulation.
On the other hand, Grb2 may also regulate Akt activity in a Ras-independent manner. This is because in addition to binding to Sos, Grb2 can use its SH3 domain to bind to other proline-rich containing proteins, such as PI3 kinase (Wang et al., 1995) , and Grb2-associated binder protein-1 (Gab-1) (HolgadoMadruga et al., 1996) . Both PI3 kinase and Gab-1 can stimulate Akt activity (Holgado-Madruga et al., 1997; Wang et al., 1995) . The activation of Akt by PI3 kinase or Gab-1 appears to be Ras-independent because the binding of Grb2 to PI3 kinase or Gab-1 can exclude Sos from binding to Grb2, and could potentially stimulate Akt activity without stimulating Erk1,2 activity (Holgado-Madruga et al., 1997; Wang et al., 1995) . In that case, inhibition of Grb2 expression may induce Akt inactivation without inducing Erk1,2 inactivation. This postulation is similar to what we have described here for our ErbB2-activated breast cancer systems. However, since Grb2 inhibition was found to decrease Ras activity in ®broblasts transfected with ErbB2 (Xie et al., 1995) , we believe that Grb2 inhibition induces Akt inactivation via Ras inactivation.
Even though Akt is known to be activated in response to PI3 kinase activation, some studies have suggested that Akt could be activated by PI3 kinaseindependent mechanisms. For example, Filippa's studies suggested that Akt could be activated by protein kinase A (Filippa et al., 1999) . When Akt is activated by PI3 kinase, Ser 473 is always phosphorylated (Franke et al., 1997; Alessi and Cohen, 1998) ; however in Filippa's studies, protein kinase A activation of Akt did not induce Ser 473 phosphorylation (Filippa et al., 1999) . Since our studies showed that Ser 473 phosphorylation of Akt was modulated by Grb2, we believe that Grb2 inhibition is followed by PI3 kinase inactivation, and thus Akt inactivation. We are currently investigating whether Ras and/or PI3 kinase is involved in the regulation of Akt activity by Grb2 protein.
Heregulin can stimulate the activation of Erk1,2 and Akt (Fiddes et al., 1995; Marte et al., 1995; SeppLorenzino et al., 1996; Liu et al., 1999) ; both Erk1,2 and Akt are expected to play major roles in heregulininduced cellular processes. However, here we report that activation of ErbB2 by heregulin (as well as by ErbB2 overexpression) uses Grb2 to preferentially stimulate Akt, not Erk1,2, activity to eect breast cancer mitogenesis. There have been reports demonstrating that Akt is preferred to Erk1,2 in other heregulin-induced cellular processes, such as cell cycle progression (Daly et al., 1999) and cellular aggregation (Tang et al., 1999) . Wortmannin and LY294002, which can inhibit PI3 kinase and therefore Akt activities, can inhibit cell cycle progression and aggregation of breast cancer cells induced by heregulin (Daly et al., 1999; Tang et al., 1999) . On the other hand, PD98059, which can inhibit MEK and therefore Erk1,2 activities, cannot inhibit these same breast cancer cellular processes induced by heregulin (Daly et al., 1999; Tang et al., 1999) . So, it appears that heregulin may prefer PI3 kinase/Akt pathway to MEK/Erk1,2 pathway in regulating mitogenesis, cell cycle progression, and aggregation of breast cancer cells. It will be very interesting to determine what kinds of cellular processes heregulin will use Erk1,2 for, and the identity of those adaptor proteins that are involved in mediating the activation of Erk1,2 by heregulin.
Materials and methods
Cell lines
T-47D, BT-474, and MDA-MB-453 cells were obtained from ATCC (Manassas, VA, USA). MCF-7 cells transfected with the control neomycin vector (MCF7/V) or the heregulin b-2 gene (MCF7/T7) were obtained from Dr Ruth Lupu (Tang et al., 1996) . Cells were cultured in DMEM/F12 medium supplemented with 5 or 10% heat-inactivated FBS at 378C in a 5% CO 2 humidi®ed incubator. ) were purchased from New England Biolabs (Beverly, MA, USA). These antibodies had been reliably used by us (Tari et al., 1999; Tari and Lopez-Berestein, 2000) and others (Li et al., 1998; Majeti et al., 1998) to measure the phosphorylation, i.e. activation, levels of Erk1,2 and Akt. Antimouse or antirabbit secondary antibodies were obtained from Amersham Life Sciences (Cleveland, OH, USA).
Antibodies
Liposomal oligodeoxynucleotides (oligos)
Nuclease resistant P-ethoxy oligos (18 bases) were purchased from Oligos Etc., Inc. (Willsonville, OR, USA). We have previously reported the sequences of the Grb2 antisense and the control oligos (Tari et al., 1997 (Tari et al., , 1999 ). Grb2 antisense: 5'-ATATTTGGCGATGGCTTC-3'; Random control oligo: 5'-GGGCTTTTGAACTCTGCT-3'. Grb2 antisense and control oligos were mixed with dioleoyl-phosphocholine (Avanti Polar Lipids, Alabaster, AL, USA) in the presence of tertiary butanol and prepared as described (Tari et al., 1997 (Tari et al., , 1999 .
Cell growth and viability assay
Breast cancer cells were seeded between 2 ± 8610 3 cells/well in 96-well plates in 0.1 ml of DMEM/F12 medium supplemented with 5 or 10% FBS. The next day, heregulin b1 (Neomarkers, Union City, CA, USA) and/or liposomal oligos were added to cells for 5 ± 6 days before cell growth and viability was measured by the CellTiter 96 1 AQueous nonradioactive assay (Promega, Madison, WI, USA). This assay measures the conversion of a tetrazolium compound, MTS, into water-soluble MTS-formazan. Each experiment was done in triplicates and repeated at least three times.
Western blots
Breast cancer cells were incubated with liposomal oligos for 3 days. Untreated and treated cells were lysed, and protein lysates were prepared. Proteins were elecrophoresed and electrotransferred as described (Tari et al., 1999; Tari and Lopez-Berestein, 2000) . The membranes were incubated with anti-Grb2 antibodies, anti-phosphorylated Erk1,2 antibodies, or anti-phosphorylated Akt antibodies, and protein bands were visualized by enhanced chemiluminescence (Amersham Life Sciences). The membranes were then stripped and reincubated with antibodies speci®c for Actin, Erk1,2, or Akt. Protein bands were visualized by enhanced chemiluminescence. Images were scanned and quantitated by an Alpha Innotech densitometer using the Alpha Imager application program (Alpha Innotech, San Leandro, CA, USA). 
